Clinical Trials Logo

Leukemia, Myeloid clinical trials

View clinical trials related to Leukemia, Myeloid.

Filter by:

NCT ID: NCT05471700 Recruiting - Clinical trials for Leukemia, Myeloid, Acute

Single Arm Study of Azacitidine and Venetoclax for Treatment of Newly Diagnosed Fit Acute Myeloid Leukemia Patients

Start date: September 1, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The goal of this clinical research study is to evaluate the safety and efficacy of Azacytidine in combination with Venetoclax in patients with newly diagnosed fit acute myeloid leukemia.

NCT ID: NCT05471323 Recruiting - Clinical trials for Acute Myeloid Leukemia

Phase I Clinical Trial of RC1012 Injection in Patients With r/r AML

Start date: January 14, 2021
Phase: Phase 1
Study type: Interventional

To evaluate the safety and tolerability of RC1012 infusion in patients with relapsed or refractory Acute Myelocytic Leukemia (r/r AML).

NCT ID: NCT05470140 Recruiting - Clinical trials for Acute Myeloid Leukemia

A Phase 1 Study of WU-NK-101 in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)

Start date: July 1, 2023
Phase: Phase 1
Study type: Interventional

This study is a Phase 1, open-label, dose escalation, and cohort expansion study designed to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary anti-leukemic activity of WU-NK-101 in R/R AML.

NCT ID: NCT05458258 Recruiting - Clinical trials for Acute Myeloid Leukemia

Studying Malnutrition And Sarcopenia In Older Adults With Acute Myeloid Leukemia

Start date: March 1, 2023
Phase:
Study type: Observational

This study will explore how malnutrition (poor nutrition/diet) and sarcopenia (a condition that causes a loss of muscle and bone mass) affects study participants over the age of 60 with acute myeloid leukemia (AML) who will receive induction chemotherapy (chemotherapy given as the first treatment to help cancer go into remission) and/or cancer drugs as part of standard care for AML. By studying how these nutritional and skeletal factors, doctors leading this study hope to learn how malnutrition and sarcopenia may be able to predict certain outcomes --such as how long study participants with poor nutrition and muscle loss can live after chemotherapy- for older (age 60+) individuals with AML.

NCT ID: NCT05457010 Recruiting - Clinical trials for Acute Myeloid Leukemia

Phase I Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory AML or High-risk MDS

Start date: November 28, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and preliminary activity of ARC-T cells and SPRX002 in participants with relapsed or refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS)

NCT ID: NCT05456269 Withdrawn - Clinical trials for Acute Myeloid Leukemia

A Study of Bisantrene Combined With Cytarabine or With Decitabine for Adult Subjects With Extramedullary AML and MDS

BISECT
Start date: July 29, 2022
Phase: Phase 1
Study type: Interventional

This is a two strata Phase 1b study to assess the safety and efficacy of bisantrene (RC110) in combination with a) cytarabine arabinoside (Ara-C) treatment for patients with relapsed or refractory (R/R) Acute Myeloid Leukemia (AML) with extramedullary disease and able to tolerate intensive chemotherapy; b) in combination with decitabine/cedazuridune (ASTX727) new or relapsed or refractory AML or high risk MDS or CMML with extramedullary disease and unable or not willing to have intensive chemotherapy.

NCT ID: NCT05456191 Recruiting - Clinical trials for Philadelphia Chromosome-Positive Chronic Myeloid Leukemia

A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)

ASC4START
Start date: November 21, 2022
Phase: Phase 3
Study type: Interventional

The study is designed to compare the tolerability of asciminib versus nilotinib for the treatment of newly diagnosed, previously untreated patients with Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP).

NCT ID: NCT05456048 Completed - Clinical trials for Refractory Acute Myeloid Leukemia

Influence of Molecular Abnormalities on Response of VAH vs. VEN+HMA in RR-AML

Start date: December 3, 2018
Phase:
Study type: Observational

The aim of this study is to reveal the influence of gene mutations on the treatment response of the regimen of HHT combined with Venetoclax plus AZA versus venetoclax plus HMA in the salvage therapy of RR-AML.

NCT ID: NCT05455294 Recruiting - Clinical trials for Acute Myeloid Leukemia

Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms

Start date: July 18, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this research study is to test the safety of a new three drug combination of navitoclax, decitabine, and venetoclax to treat advanced myeloid malignancies. The names of the drugs involved in this study are: - Venetoclax - Decitabine - Navitoclax

NCT ID: NCT05453903 Recruiting - Clinical trials for Leukemia, Myeloid, Acute

A Study of JNJ-75276617 in Combination With Acute Myeloid Leukemia (AML) Directed Therapies

Start date: October 4, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the recommended Phase 2 dose (RP2D) candidate(s) of JNJ-75276617 in combination with AML directed therapies (dose selection) and further to evaluate safety and tolerability of JNJ-75276617 in combination with AML directed therapies at the RP2D(s) (dose expansion).